Riskpilot← Back to searchSign inGet full accessExpreS2ion Biotech Holding AB
ABActiveOrg 5590333729Rönnowsgatan 8 CActivities of holding companies · NACE 6421Est. 20150 employees
Revenue 2024
SEK 558K
0% vs 2023
EBITDA margin
-982.8%
+10% vs 2023
Equity ratio
97.0%
Financial strength
Net profit 2024
SEK -65M
+75% vs 2023
| Revenue | SEK 558K | +0% |
| EBITDA | SEK -5,5M | +10% |
| Net profit | SEK -65M | +75% |
| Total assets | SEK 79,9M | -29% |
| Equity | SEK 77,5M | -29% |
| Employees | 0 | — |
Legal name
ExpreS2ion Biotech Holding AB
Org number
5590333729
Legal form
Aktiebolag
NACE code
6421 · Activities of holding companies
Founded
3 november 2015
Share capital
SEK 11 815 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av ledamöterna i förening med Frandsen, Bent Ulrich Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall direkt eller indirekt genom dotterbolag bedriva verksamhet inom produktionen av läkemedelsproteiner, samt utveck- ling av protein produktionsteknik samt därmed förenlig verksam- het. Bolaget skall också bedriva styrning av dotterbolagen. Bola- get skall även kunna förvalta fast och lös egendom.
Address
Rönnowsgatan 8 C
Email
buf@expres2ionbio.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 335 | 368 | 508 | 558 | 558 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 703 | −6 803 | −6 718 | −6 070 | −5 484 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −2 703 | −6 803 | −6 718 | −6 070 | −5 484 |
| Net financials | −4 778 | 835 | 1 505 | −257 110 | −59 485 |
| Profit before tax | −4 897 | −5 969 | −5 213 | −263 180 | −64 969 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 897 | −5 969 | −5 213 | −263 180 | −64 969 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 171 445 | 253 066 | 321 521 | 111 924 | 79 866 |
| Equity | 169 359 | 251 672 | 319 897 | 109 345 | 77 504 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 086 | 1 394 | 1 624 | 2 579 | 2 362 |
| Total debt | 2 086 | 1 394 | 1 624 | 2 579 | 2 362 |
EBITDA margin
-982.8%
This company
15.8%
Market median
-6320% vs market
20202024
Equity ratio
97.0%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
-83.8%
This company
18.4%
Market median
-555% vs market
20202024
Net profit margin
-11643.2%
This company
8.1%
Market median
-143843% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JD Chief Auditor | Chief Auditor | 2022 |
YW Authorized Recipient of Service | Authorized Recipient of Service | 2021 |
BU Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (4) | ||
OC Chief Auditor | Chief Auditor | 2020 – 2022 |
TH Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2021 |
EL Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2020 |
BA Chief Auditor | Chief Auditor | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2026 | |
| Chairman | 2020 | |
| Former (4) | ||
| Board of Directors | 2022 – 2026 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ExpreS2ion Biotech Holding AB (this company)
Expres2ion Biotechnologies ApsEXPRES2ION BIOTECHNOLOGIES APSBoard members of ExpreS2ion Biotech Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Daniel Åkeborg | Chief Auditor | 0 companies |
| Yvonne Wenche Catarina Flovén | Authorized Recipient of Service | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Bent Ulrich Frandsen | Chief Executive Officer | 0 companies |
| Torben Hede | Authorized Recipient of Service | 0 companies |
| Ewa Liselotte Garpdal | Authorized Recipient of Service | 0 companies |
| Bengt Anders Ekenberg | Chief Auditor | 0 companies |
| Karin Garre | Board of Directors | 0 companies |
| Sara Sande | Board of Directors | 0 companies |
| Gitte Laurette Pedersen Botero | Board of Directors | 0 companies |
| Jakob Knudsen | Board of Directors | 0 companies |
| Michel Jean M. Baijot | Board of Directors | 0 companies |
| Sara Sande | Board of Directors | 0 companies |
| Martin Roland Jensen | Chairman | 0 companies |
| Allan Rosetzsky | Board of Directors | 0 companies |